Liver function may change how radiprodil works – new study aims to find out
NCT ID NCT07457229
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing how the drug radiprodil behaves in people with mild, moderate, or severe liver problems compared to healthy adults. About 40 participants will receive a single dose and be monitored for about a week. The goal is to see if liver impairment affects drug levels in the body, which will help guide safe dosing in future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiprodil (oral suspension)
What this could lead to
If successful, this study could help doctors determine the right dose of radiprodil for people with liver problems, making future treatments safer.
What could go wrong
This is a very early Phase 1 study with only 40 people. It is designed to measure drug levels, not to treat any disease, so there is no direct benefit to participants. Liver impairment may affect results unpredictably.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Epic Medical Research
RECRUITINGDeSoto, Texas, 75115, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact